Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306351 | 1.00 | PDE2A (0.61) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL11121799 | 0.92 | PDE2A (0.59) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL750344 | 0.86 | PDE2A (0.72) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL11126005 | 0.86 | PDE2A (0.56) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL8764444 | 0.83 | PDE2A (0.70) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL11123492 | 0.82 | HTR1A (0.55) | PDE2AHTR1ABCHETP53MDM2 | |
| SCHEMBL11123141 | 0.82 | HTR1A (0.59) | PDE2AHTR1ABCHEPTPN2PTPN1 | |
| SCHEMBL11420439 | 0.80 | PDE2A (0.61) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL11427985 | 0.80 | PDE2A (0.64) | PDE2AHTR1ABCHEADORA2AADORA2B | |
| SCHEMBL5961364 | 0.80 | PDE2A (0.64) | PDE2AHTR1ABCHEADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | PDE2A 329/4885HTR1A 1247/4885BCHE 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.